CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

被引：0
|
作者：
Goadsby, P. [1 ,2 ,3 ]
Dodick, D. [4 ]
Spierings, E. [5 ,6 ,7 ]
Scherer, J. [8 ]
Sweeney, S. [9 ]
Grayzel, D. [9 ]
机构：
[1] Kings Coll London, NIHR Wellcome Trust Clin Res Facil KCL, London WC2R 2LS, England
[2] Kings Coll London, Dept Neurol UCSF, London WC2R 2LS, England
[3] Univ Calif San Francisco, London, England
[4] Mayo Clin, Dept Neurol, Phoenix, AZ USA
[5] Harvard Univ, Brigham & Womens Hosp, Dept Neurol BWH, Sch Med, Boston, MA 02115 USA
[6] Harvard Univ, Brigham & Womens Hosp, Headache & Face Pain Program, Sch Med, Boston, MA 02115 USA
[7] Tufts Sch Dent Med, Boston, MA USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Arteaus Therapeut, Cambridge, MA USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2014年 / 15卷
关键词：
Placebo; Migraine; Calcitonin; Injection Site; Secondary Endpoint;
D O I：
10.1186/1129-2377-15-S1-G10
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EHMTI-0178
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Dodick, D.
    Goadsby, P. J.
    Spierings, E. L.
    Scherer, J.
    Sweeney, S.
    Grayzel, D.
    HEADACHE, 2014, 54 (08): : 1430 - 1430
  • [2] CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Dodick, David
    Goadsby, Peter
    Spierings, Egilius
    Scherer, Joel
    Sweeney, Steven
    Grayzel, David
    NEUROLOGY, 2014, 83 (02) : E39 - E40
  • [3] EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
    P Goadsby
    D Dodick
    E Spierings
    J Scherer
    S Sweeney
    D Grayzel
    The Journal of Headache and Pain, 2014, 15
  • [4] Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
    Dodick, David W.
    Goadsby, Peter J.
    Spierings, Egilius L. H.
    Scherer, Joel C.
    Sweeney, Steven P.
    Grayzel, David S.
    LANCET NEUROLOGY, 2014, 13 (09): : 885 - 892
  • [5] Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine
    Oakes, T.
    Zhang, Q.
    Ferguson, M.
    Skljarevski, V
    Martinez, J. M.
    Johnson, K. W.
    Schacht, A. L.
    Due, M. R.
    Goadsby, P.
    Dodick, D. W.
    HEADACHE, 2016, 56 : 68 - 68
  • [6] EFFICACY AND SAFETY OF LY2951742 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY IN PATIENTS WITH MIGRAINE
    Skljarevski, V.
    Oakes, T.
    Ferguson, M.
    Zhang, Q.
    Martinez, J.
    Johnson, K.
    Schacht, A.
    Due, M.
    Goadsby, P.
    Dodick, D.
    CEPHALALGIA, 2016, 36 : 42 - 42
  • [7] Sustained Response Outcomes from a Phase 2a, Randomized, Double-blind, Placebo-controlled Study of LY2951742, a Monoclonal Antibody to Calcitonin Generelated Peptide, for the Prevention of Migraine: A Post-hoc Analysis
    Dodick, D. W.
    Goadsby, P. J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V
    Martinez, J.
    HEADACHE, 2015, 55 : 177 - 177
  • [8] Onset of efficacy of LY2951742 in migraine prevention: post-hoc analysis of phase 2a, randomized, double-blind, placebo-controlled study data of a calcitonin gene-related peptide monoclonal antibody
    Goadsby, P. J.
    Dodick, D.
    Martinez, J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V.
    CEPHALALGIA, 2015, 35 : 55 - 55
  • [9] Sustained response outcomes from a phase 2a, randomized, double-blind, placebo-controlled study of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a post-hoc analysis
    Dodick, D. W.
    Goadsby, P. J.
    Skljarevski, V.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Martinez, J.
    CEPHALALGIA, 2015, 35 : 52 - 52
  • [10] Onset of Efficacy of LY2951742 in Migraine Prevention: Data from a Phase 2a, Randomized, Double-blind, Placebo-controlled Study of a Monoclonal Antibody to Calcitonin Gene-related Peptide (a Post-hoc Analysis)
    Goadsby, P. J.
    Dodick, D. W.
    Martinez, J.
    Ferguson, M.
    Oakes, T.
    Tanaka, Y.
    Ni, X.
    Zhang, Q.
    Due, M.
    Skljarevski, V
    HEADACHE, 2015, 55 : 177 - 178
12345